RenovoRx Operating Expenses 2020-2025 | RNXT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

RenovoRx operating expenses from 2020 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

RenovoRx operating expenses from 2020 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$225.3B
Amgen (AMGN)	$164.8B
Gilead Sciences (GILD)	$144.5B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$98.6B
CSL (CSLLY)	$85.4B
GSK (GSK)	$77.7B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$42.9B
Argenex SE (ARGX)	$36.2B
BioNTech SE (BNTX)	$27.7B
Royalty Pharma (RPRX)	$20.6B
Insmed (INSM)	$19.7B
Biogen (BIIB)	$19.3B
Illumina (ILMN)	$17.3B
Genmab (GMAB)	$15B
Genmab (GNMSF)	$15B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.2B
Exelixis (EXEL)	$12.4B
QIAGEN (QGEN)	$11.5B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.2B
Bio-Techne Corp (TECH)	$9.2B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8B
Roivant Sciences (ROIV)	$7.9B